Zacks Research Issues Negative Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Research analysts at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for shares of Sanofi in a note issued to investors on Wednesday, March 5th. Zacks Research analyst K. Shah now forecasts that the company will post earnings per share of $1.57 for the quarter, down from their prior forecast of $1.59. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q2 2026 earnings at $1.00 EPS and FY2027 earnings at $4.75 EPS.

A number of other brokerages have also recently issued reports on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Stock Down 1.0 %

Shares of Sanofi stock opened at $58.74 on Monday. The business’s fifty day moving average price is $53.08 and its two-hundred day moving average price is $52.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $149.07 billion, a P/E ratio of 23.59, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Synergy Asset Management LLC bought a new position in Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. increased its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the period. Bessemer Group Inc. increased its stake in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after acquiring an additional 242 shares during the last quarter. Lee Danner & Bass Inc. bought a new position in Sanofi in the fourth quarter valued at approximately $31,000. Finally, Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.